Nomura Holdings
VRTX icon

Nomura Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Nomura Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.81M Sell
13,700
-8,500
-38% -$3.77M 0.01% 676
2026
Q1 		$9.91M Buy
22,200
+700
+3% +$326K 0.03% 430
2025
Q4 		$9.75M Sell
21,500
-12,900
-38% -$5.56M 0.01% 521
2025
Q3 		$13.5M Sell
34,400
-6,500
-16% -$2.72M 0.02% 421
2025
Q2 		$18.2M Buy
40,900
+12,900
+46% +$5.94M 0.04% 269
2025
Q1 		$13.6M Buy
28,000
+6,000
+27% +$2.8M 0.03% 386
2024
Q4 		$8.86M Sell
22,000
-2,800
-11% -$1.3M 0.01% 545
2024
Q3 		$11.5M Buy
24,800
+9,800
+65% +$4.71M 0.03% 398
2024
Q2 		$7.03M Buy
15,000
+9,000
+150% +$3.91M 0.01% 574
2024
Q1 		$2.51M Buy
+6,000
New +$2.54M 0.01% 843
2018
Q2 		– Sell
-176,400
Closed -$28.7M – 1594
2018
Q1 		$28.7M Buy
+176,400
New +$28.8M 0.05% 201

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nomura Holdings's VRTX Position: Q2 2026 in Review

Nomura Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $1.37M and bringing the position to 29,198 shares worth $14.5M. The position accounts for 0.02% of the portfolio, ranked #445.

Nomura Holdings first reported a position in VRTX in Q2 2013 and has held it in 42 quarters since. The position peaked at $26.7M in Q3 2025. 1,759 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nomura Holdings held 29,198 shares of Vertex Pharmaceuticals worth $14.5M as of Q2 2026.
  • Nomura Holdings bought 3,097 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.37M.
  • Vertex Pharmaceuticals made up 0.02% of Nomura Holdings's portfolio in Q2 2026, its #445 holding.
  • Nomura Holdings first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Nomura Holdings's Vertex Pharmaceuticals position peaked at $26.7M in Q3 2025.
  • 1,759 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.